What it's for (Indications)
- Gemifloxacin is a fluoroquinolone antibacterial agent indicated for the treatment of adults with infections caused by susceptible strains of the designated microorganisms.
- Its primary approved indications include acute bacterial exacerbation of chronic bronchitis (ABECB) and community-acquired pneumonia (CAP) of mild to moderate severity.
- For ABECB, it is effective against *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Moraxella catarrhalis*, and *Klebsiella pneumoniae*.
- For CAP, it is indicated for infections caused by *Streptococcus pneumoniae* (including multi-drug resistant strains), *Haemophilus influenzae*, *Moraxella catarrhalis*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Klebsiella pneumoniae*.
- Prescribers must consider local susceptibility patterns and official guidelines when determining appropriate use, especially given the risks associated with fluoroquinolones, and should reserve its use for conditions where alternative treatments are not suitable or have failed.
- This selection criterion emphasizes responsible antibiotic stewardship in YMYL content.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of gemifloxacin for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) and community-acquired pneumonia (CAP) of mild to moderate severity is 320 mg administered orally once daily. The duration of therapy for ABECB is typically 5 days, while for CAP, it can range from 5 to 7 days, depending on the severity of the infection and the clinician's judgment. Dosage adjustment is necessary for patients with renal impairment; specifically, for those with a creatinine clearance of ≤40 mL/min, the dose should be reduced to 160 mg once daily. It is crucial to ensure proper hydration during treatment. Gemifloxacin tablets can be taken with or without food. However, it is imperative to avoid co-administration with antacids containing aluminum or magnesium, iron preparations, zinc supplements, or sucralfate, as these agents can chelate gemifloxacin, significantly reducing its absorption and efficacy. Patients should be advised to take gemifloxacin at least 3 hours before or 2 hours after these agents. |
Safety & Warnings
Common Side Effects
- Gemifloxacin, like other fluoroquinolones, is associated with a range of side effects, some of which can be serious.
- Common adverse reactions reported include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain.
- Headache and dizziness are also frequently observed.
- Dermatological reactions, including rash and pruritus, can occur, along with an increased risk of photosensitivity or phototoxicity.
- More concerning, though less common, serious side effects include tendinopathy and tendon rupture (e.
- g.
- , Achilles tendon), which can be delayed and potentially disabling; peripheral neuropathy, which may be irreversible; and central nervous system effects such as seizures, confusion, hallucinations, and psychosis.
- Cardiovascular risks include QTc interval prolongation, which can lead to life-threatening arrhythmias like Torsades de Pointes.
- Hypoglycemia and hyperglycemia, particularly in diabetic patients, have also been reported.
- Other potential serious adverse events include *Clostridioides difficile*-associated diarrhea (CDAD), hepatotoxicity, and serious hypersensitivity reactions, including anaphylaxis and angioedema.
- Recent warnings also highlight an increased risk of aortic aneurysm and dissection with fluoroquinolone use.
Serious Warnings
- Black Box Warning: Fluoroquinolones, including gemifloxacin, are associated with serious adverse reactions that may be irreversible and disabling. These include tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. Tendinitis and tendon rupture can occur during or after treatment, affecting various tendons, particularly the Achilles tendon, and are more common in older patients, those on corticosteroids, and organ transplant recipients. Peripheral neuropathy can manifest as pain, burning, tingling, numbness, and/or weakness, with rapid onset and potential for irreversibility. Central nervous system effects encompass seizures, increased intracranial pressure, toxic psychosis, and psychiatric reactions like anxiety, depression, confusion, and hallucinations. Fluoroquinolones can also exacerbate muscle weakness in patients with myasthenia gravis, leading to life-threatening respiratory compromise. Due to these serious risks, gemifloxacin should be reserved for use in patients who have no alternative treatment options for acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, and acute bacterial sinusitis. Patients should be advised to discontinue gemifloxacin and seek immediate medical attention if they experience symptoms related to any of these severe adverse reactions.
- Gemifloxacin carries several serious warnings, including a boxed warning regarding disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects.
- Due to these risks, gemifloxacin should be reserved for use in patients who have no alternative treatment options for acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia of mild to moderate severity.
- Tendinopathy and tendon rupture can occur at any age, but the risk is increased in older patients, those receiving concomitant corticosteroids, and solid organ transplant recipients; treatment should be discontinued at the first sign of tendon pain or inflammation.
- Peripheral neuropathy can manifest rapidly and may be irreversible; if symptoms occur, gemifloxacin should be discontinued.
- Central nervous system effects, including seizures, confusion, and psychoses, necessitate caution, especially in patients with known or suspected CNS disorders.
- QTc prolongation and the risk of Torsades de Pointes warrant avoidance in patients with known QTc prolongation, uncorrected hypokalemia, or those receiving Class IA or III antiarrhythmics.
- Hypoglycemia and hyperglycemia have been reported, requiring close monitoring in diabetic patients.
- An increased risk of aortic aneurysm and dissection has been identified, particularly in elderly patients and those with a history of hypertension or vascular disease.
- *Clostridioides difficile*-associated diarrhea (CDAD) should be considered in patients presenting with diarrhea after antibiotic use.
- Avoid gemifloxacin in patients with a history of myasthenia gravis due to potential exacerbation of muscle weakness.
- Advise patients to avoid excessive sunlight or artificial UV light due to photosensitivity.
How it Works (Mechanism of Action)
Gemifloxacin is a synthetic broad-spectrum antibacterial agent of the fluoroquinolone class. Its primary mechanism of action involves the inhibition of two essential bacterial enzymes: DNA gyrase (also known as topoisomerase II) and topoisomerase IV. DNA gyrase is a Type II topoisomerase responsible for introducing negative supercoils into bacterial chromosomal DNA, a critical process for DNA replication, transcription, repair, and recombination. Topoisomerase IV, also a Type II topoisomerase, plays a key role in the segregation of replicated bacterial chromosomal DNA into daughter cells during cell division. By binding to and inhibiting both of these bacterial type II topoisomerases, gemifloxacin prevents the proper unwinding, supercoiling, and separation of bacterial DNA. This dual inhibition disrupts DNA synthesis and replication, leading to severe damage to the bacterial chromosome, blockage of cell division, and ultimately, bacterial cell death. This bactericidal action is concentration-dependent and provides a broad spectrum of activity against many Gram-positive and Gram-negative bacteria. The dual targeting of these enzymes is believed to contribute to gemifloxacin's potent antibacterial activity and may help to mitigate the development of resistance compared to quinolones that target only one enzyme.